Cumulus cell (CC) gene expression is being explored as an additional method to morphological scoring to choose the embryo with the highest chance to pregnancy. The present invention relates to a novel method of identifying biomarker genes for evaluating the competence of a mammalian oocyte in giving rise to a viable pregnancy after fertilization, based on the use of live birth and embryonic development as endpoint criteria for the oocytes to be used in an exon level analysis of potential biomarker genes. The invention further provides CC-expressed biomarker genes thus identified, as well as prognostic models based on the biomarker genes identified using the methods of the present invention.

The technology disclosed relates to classification of process cycle images to predict success or failure of process cycles. The technology disclosed includes capturing and processing images of sections arranged on an image generating chip in genotyping process. Image description features of production cycle images are created and given as input to classifiers. A trained classifier separates successful production images from unsuccessful or failed production images. The failed production images are further classified by a trained root cause classifier into various categories of failure.

The technology disclosed relates to classification of process cycle images to predict success or failure of process cycles. The technology disclosed includes capturing and processing images of sections arranged on an image generating chip in genotyping process. Image description features of production cycle images are created and given as input to classifiers. A trained classifier separates successful production images from unsuccessful or failed production images. The failed production images are further classified by a trained root cause classifier into various categories of failure.

Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of bio -markers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).

Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of bio -markers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).

Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes exhibit improved alpha-glucan product yields and/or lower leucrose yields, for example. Further disclosed are reactions and methods in which engineered glucosyltransferases are used to produce alpha-glucan.

Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. Further disclosed herein are classifiers for analyzing a cancer.

Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. Further disclosed herein are classifiers for analyzing a cancer.

Provided is a method for providing, on the basis of genetic marker matching of heterologous organisms, a genetic testing service by using genetic markers of a model organism as genetic markers of a target organism, the method comprising the steps of: selecting at least one genetic marker of a pre-stored model organism; comparing genomic information of the model organism to genomic information of a target organism to be subjected to a genetic testing service, when the selected at least one genetic marker is a previously known genetic marker through pre-analyzed information; and providing a genetic mutation-based genetic report about a target organism on the basis of the results of comparing genomic information of target and model organisms.

Provided is a method for providing, on the basis of genetic marker matching of heterologous organisms, a genetic testing service by using genetic markers of a model organism as genetic markers of a target organism, the method comprising the steps of: selecting at least one genetic marker of a pre-stored model organism; comparing genomic information of the model organism to genomic information of a target organism to be subjected to a genetic testing service, when the selected at least one genetic marker is a previously known genetic marker through pre-analyzed information; and providing a genetic mutation-based genetic report about a target organism on the basis of the results of comparing genomic information of target and model organisms.